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AT-rich interaction domain 1A (ARID1A) is a tumor suppressor protein involved in endometrioid carcinogenesis. The
expression of ARID1A may be lost in the premalignant phase. Our aim was to assess ARID1A as: (i) diagnostic marker
to diﬀerentiate premalignant endometrial hyperplasia (EH) form benign EH; (ii) prognostic marker for the risk of occult
cancer in premalignant EH. A systematic review and meta-analysis were performed by searching electronic databases
from their inception to October 2018 for all studies assessing ARID1A in EH by immunohistochemistry. Sensitivity,
speciﬁcity, positive and negative likelihood ratios (LR+ and LR), and diagnostic odds ratio (DOR) were calculated for
both diagnostic and prognostic accuracy. LR+ > 5, LR < 0.2, DOR > 25 deﬁned good accuracy; LR+ > 10,
LR < 0.1, DOR > 100 deﬁned excellent accuracy. Seven studies with 467 EH were included. As diagnostic marker,
ARID1A showed sensitivity = 0.12, speciﬁcity = 0.99, LR+ = 4.34, LR = 0.85, DOR = 5.12. As prognostic marker for
occult cancer, ARID1A showed sensitivity = 0.33, speciﬁcity = 0.99, LR+ = 20.70, LR = 0.49, DOR = 49.59. In con-
clusion, ARID1A loss is highly speciﬁc, but little accurate as diagnostic marker of premalignant EH. Instead, ARID1A
loss in premalignant EH is an accurate and almost perfectly speciﬁc prognostic marker for coexistent cancer.
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Endometrial hyperplasia (EH) is a pathology char-
acterized by hyperplastic changes in endometrial
glandular and stromal structures lining the uterine
cavity (1), (2). EH may represent either a functional
proliferation (caused by unopposed estrogens
action) or a premalignant lesion (driven by genetic
mutations) (1–3). Premalignant EH can progress to
endometrial carcinoma (EC) of endometrioid type
(3), (3).
The distinction between benign and premalignant
EH is crucial in terms of the choice of treatment.
Benign EH may be managed by follow-up alone or
by progestogens when symptomatic. Premalignant
EH requires total hysterectomy; a conservative
approach based on progestogens may be chosen in
selected cases (4). The diﬀerential diagnosis is per-
formed by histologic examination. Two alternative
classiﬁcation systems have been proposed for this
purpose (2), (3). The WHO system diﬀerentiates
‘atypical EH’ (premalignant) from ‘non-atypical
EH’ (benign), based on the presence of cytologic
atypia (1), (2), (5), (6). The endometrial intraepithe-
lial neoplasia (EIN) system diﬀerentiate ‘EIN’ (pre-
malignant) from ‘benign EH’ based on glandular
crowing, lesion diameter > 1 mm and cytology dif-
ferent from adjacent endometrium, careful exclu-
sion of benign mimics and cancer (2), (3), (5), (6).
However, histologic diagnosis of EH is known to
be diﬃcult and aﬀected by several issues, such as
inter-observer variability, unclear features, or tissue
paucity particularly in biopsy specimens (2), (7). To
overcome misdiagnosis, molecular biology and theReceived 19 April 2019. Accepted 20 June 2019
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less expensive immunohistochemistry have been
more and more at the heart of researches (8). In
fact, many diﬀerent studies have been conducted
and a great number of biomarkers have been inves-
tigated to help pathologists in diﬀerentiating pre-
malignant from benign lesions (2). One of the most
interesting immunohistochemical marker has been
AT-rich interaction domain 1A (ARID1A), a
tumor suppressor protein which can be deﬁcient in
EC, particularly in the endometrioid type (2).
Despite being proposed by 2017 ESGO guidelines
as a useful marker in EH (9), its relevance as a
diagnostic or prognostic marker has never been
deﬁned.
The aim of our study was to deﬁne the clinical
usefulness of ARID1A in two diﬀerent ﬁelds: (i) as
a diagnostic marker to diﬀerentiate premalignant
EH from benign EH, by calculating its diagnostic
accuracy; (ii) as a prognostic marker for the risk of
cancer in EH, by calculating its prognostic accu-
racy.
MATERIALS AND METHODS
Study design
Methods for electronic search, study selection, risk of bias
assessment, data extraction and data analysis were deﬁned
a priori. All review stages were conducted independently
by three authors (AR, AT, MC). Any disagreement was
resolved by discussion with a fourth author (GS).
The study was reported according to the Preferred
Reporting Item for Systematic Reviews and Meta-analyses
(PRISMA) statement (10).
Search strategy and study selection
MEDLINE, Scopus, Web of Sciences, and Google Scholar
were searched for relevant articles from the inception of
each database to October 2018. Several diﬀerent combina-
tions of the following text words were used: ‘endometrial
hyperplasia’; ‘endometrial intraepithelial neoplasia’; ‘en-
dometrial cancer’; ‘EIN’; ‘precancer’; ‘premalignant’; ‘pre-
cursor’; ‘ARID1A’; ‘AT-rich interaction domain 1A’;
‘BAF250’; ‘marker’; ‘biomarker’; ‘immunohistochemistry’;
‘immunohistochemical’. References of relevant articles
were also reviewed.
All peer-reviewed, retrospective or prospective studies,
assessing immunohistochemical expression of ARID1A on
histological specimen of EH were included in the system-
atic review. Exclusion criteria were as follows: case
reports, reviews, overlapping patient data with a study
already included.
Risk of bias assessment
The risk of bias assessment was based on the revised
Quality Assessment of Diagnostic Accuracy Studies
(QUADAS-2) (11). Four domains were assessed in each
study: (i) patient selection (i.e., if the patients were
consecutive); (ii) index test (i.e., if the assessment of
ARID1A expression were unbiased), (iii) reference stan-
dard (i.e., if the histomorphologic classiﬁcation was
unbiased), (iv) ﬂow and timing (i.e., if all patients were
assessed with the same tests; if all patients were
assessed with both index and reference tests). Authors’
judgments were categorized as: ‘low risk’ (adequate
methods), ‘high risk’ (inadequate methods), or ‘unclear
risk of bias’ (unclear adequacy of methods, information
not reported).
Data extraction
Data from each eligible study were not modiﬁed during
the extraction. For both diagnostic and prognostic accu-
racy assessment, two by two contingency tables were elab-
orated, considering two qualitative variables:
1. immunohistochemical expression of ARID1A,
dichotomized into ‘presence’ or ‘loss’ (for both
diagnostic and prognostic accuracy assessment);
2. histologic category of EH, dichotomized into
‘benign’ or ‘premalignant’ (for only diagnostic
accuracy assessment);
3. presence of cancer coexistent with EH, dichoto-
mized into ‘cancer’ or ‘no cancer’ (for only
prognostic accuracy assessment).
ARID1A ‘loss’ was deﬁned as a wide and complete loss
of immunostaining; the presence of only few ARID1A-
null glands was considered as ‘presence’ instead.
‘Benign’ EH included non-atypical EH according to
WHO and benign EH according to EIN system. As pro-
posed in the literature (12), the WHO category of ‘disor-
dered proliferative endometrium’ was considered as
‘benign’ EH, because it constitutes a pathologic contin-
uum with non-atypical EH and it is classiﬁed as benign
EH by the EIN system (1), (5). ‘Premalignant’ EH
included atypical EH according to WHO system and EIN
according to EIN system.
Regarding the presence of EC coexistent with premalig-
nant EH, ‘cancer’ indicated the presence of an occult EC
missed on initial biopsy and subsequently found on histo-
logic examination of hysterectomy specimen.
For meta-analysis of diagnostic accuracy, the index test
was the immunohistochemical expression of ARID1A
(‘presence’ or ‘loss’), while the reference test was the histo-
logic category of EH (‘benign’ or ‘premalignant’).
For the meta-analysis of prognostic accuracy, the index
test was the same as diagnostic accuracy evaluation, while
the reference standard was the presence of cancer coexis-
tent with EH (‘cancer’ or ‘no cancer’). In the diagnostic
accuracy analysis, premalignant EHs with ARID1A loss
were considered as ‘true positive’, benign EHs with
ARID1A loss as ‘false positive’, benign EHs with
ARID1A presence as ‘true negative’, and premalignant
EHs with ARID1A present as ‘false negative’.
In the prognostic accuracy analysis, EHs with ARID1A
loss and cancer were considered as ‘true positive’, EHs
with ARID1A loss and no cancer as ‘false positive’, EHs
with ARID1A presence and no cancer as ‘true negative’,
and EHs with ARID1A presence and cancer as ‘false neg-
ative’.
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Data analysis
For both diagnostic and prognostic accuracy, sensitivity,
speciﬁcity, positive and negative likelihood ratios (LR+
and LR), and diagnostic odds ratio (DOR) were calcu-
lated with 95% conﬁdence intervals (CI). As suggested in
the literature, LR+ > 5, LR < 0.2, and DOR > 25 were
used to deﬁne good accuracy, while LR+ > 10,
LR < 0.1, and DOR > 100 were used to deﬁne excellent
accuracy (13), (14).
For the diagnostic accuracy evaluation, all studies
assessing premalignant EHs were suitable for the sensitiv-
ity analysis; all studies assessing benign EHs were suitable
for the speciﬁcity analysis; only the studies assessing both
benign and premalignant EH were suitable for analysis of
LR+, LR, and DOR.
Statistical heterogeneity among studies was quantiﬁed
by using the inconsistency index (I2): heterogeneity was
considered insigniﬁcant for I2 < 25%, low for I2 < 50%,
moderate for I2 < 75%, and high for I2 ≥ 75%. The ran-
dom eﬀect model of DerSimonian and Laird was used,
because heterogeneity is expected in meta-analysis of diag-
nostic accuracy (14). Results were reported graphically on
forest plots.
The data analysis was performed using Review Man-
ager 5.3 (Copenhagen: The Nordic Cochrane Centre,
Cochrane Collaboration, 2014) and Meta-DiSc version 1.4
(Clinical Biostatistics Unit, Ramon y Cajal Hospital,
Madrid, Spain).
RESULTS
Selection and characteristics of the studies
At the end of the study selection process, seven
studies were ﬁnally included in the systematic
review (15–21) (Fig. 1). One study (22) was
excluded because it assessed the same sample as
another included study (19). The total sample size
was 1429, including 467 EHs. Sixty-seven EHs
were benign and 400 were premalignant. Six stud-
ies collected the specimen retrospectively and one
prospectively. Sampling methods included hystero-
scopic biopsy, dilation and curettage, and hys-
terectomy. Six studies adopted the WHO
classiﬁcation system and one study the EIN
system.
Fig. 1. Flow diagram of studies identiﬁed in the system-
atic review (Prisma template [Preferred Reporting Item for
Systematic Reviews and Meta-analyses]).
Table 1. Characteristics of the included studies
Study Country Study
design
Period of
enrollment
Sample
size
Age Diagnosis Sampling
method
Antibody
NE EP B-EH P-EH EC
Werner
et al.
(2013) (12)
Norway Prospective 2001–2009 573 n.r. 0 0 7 31 535 Hysterectomy Biosite,
AT1188a
Mao et al.
(2013) (13)
Taiwan,
USA
Retrospective n.r. 256 33–83 51 14 10 38 143 Curettage,
hysterectomy
Sigma-Aldrich
HPA005456
Zheng et al.
(2014) (14)
China Retrospective 2008–2010 134 >18 20 0 20 20 74 Hysterectomy,
biopsy
Santa Cruz
Bio-technology
sc-32761
Ayhan
et al.
(2015) (15)
Japan,
Taiwan
Retrospective n.r. 114 20–78 0 0 0 114 0 Biopsy,
curettage
Sigma-Aldrich
HPA005456
Vierkoetter
et al.
(2018) (16)
USA Retrospective 2009–2014 95 n.r. 0 0 0 95 0 Biopsy,
curettage,
hysterectomy
Abcam,
Cambridge
EPR13501MA
Niskakoski
et al.
(2018) (17)
Finland Retrospective 1996-? 160 n.r. 22 0 30 50 58 Biopsy,
hysterectomy
Sigma-Aldrich
HPA005456
Yen et al.
(2018) (18)
USA Retrospective 2005–2017 97 58.9
(loss)
57.2
(retain)
0 0 0 52 45 Biopsy,
curettage,
hysterectomy
Sigma-Aldrich
HPA005456
Total – – – 1429 - 93 14 67 400 855 – –
n.r., not reported; –, not appropriate; NE, normal endometrium; EP, endometrial polyp; B-EH, benign endometrial hyper-
plasia; P-EH, premalignant endometrial hyperplasia; EC, endometrial cancer.
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Characteristics of the included studies are
detailed in Table 1.
Risk of bias assessment
For the ‘patient selection’ domain, two studies were
considered at low risk of bias, due to the inclusion
of consecutive patients. The other studies were con-
sidered at unclear risk (information not reported).
For the ‘index test’ domain, unclear risk of bias
was assigned to one study because criteria for
immunohistochemistry interpretation were not
clearly elucidated; the remaining studies were con-
sidered at low risk.
For the ‘reference standard’ domain, no particu-
lar risk of bias was pointed out, and all included
studies were categorized at low risk.
For the ‘ﬂow and timing’ domain, two studies were
considered at unclear risk of bias (loss of patients
unexplained (20) or unclear (15)) and 5 at low risk.
Authors’ judgements are graphically reported in
Fig. 2.
Diagnostic accuracy assessment
All studies were included in the analysis of sensitiv-
ity. As a marker of premalignant EH, ARID1A
loss showed pooled sensitivity of 0.12 (95% CI,
0.09–0.15), with moderate heterogeneity among
studies (I2 = 60.6%).
Four studies were included in the analysis of
speciﬁcity. Pooled speciﬁcity was 0.99 (95% CI,
0.92–1.00), with no heterogeneity among studies
(I2 = 0.0%).
Three studies were included in the analysis of
LR+, LR, and DOR. Pooled LR+ and LR were
4.34 (95% CI, 1.06–17.74) and 0.85 (95% CI, 0.77–
0.95), respectively, with no heterogeneity
(I2 = 0.0%) in both analyses. Pooled DOR was
5.12 (95% CI, 1.15–22.78), with no heterogeneity
among studies (I2 = 0.0%) (Fig. 3).
Prognostic accuracy assessment
Two studies were available for the analysis of the
prognostic value of ARID1A in premalignant EH.
Pooled sensitivity and speciﬁcity of ARID1A loss
for coexistent cancer were 0.33 (95% CI, 0.22–0.47)
and 0.99 (95% CI, 0.94–1.00), respectively, with
high (I2 = 95.8%) and moderate (I2 = 50.5%)
heterogeneity, respectively.
Pooled LR+ and LR were 20.70 (95% CI,
4.14–103.57) and 0.49 (95% CI, 0.07–3.27), respec-
tively, with no (I2 = 0.0%) and high heterogeneity
(95.9%), respectively. Pooled DOR was 49.95
(8.46–294.8), with no heterogeneity (I2 = 0.0%)
(Fig. 4).
DISCUSSION
Main findings and interpretation
As a diagnostic marker of premalignant EH,
ARID1A loss showed almost perfect speciﬁcity, but
low sensitivity, resulting in a suboptimal accuracy.
As a marker of coexistent cancer in premalignant
EH, ARID1A showed good accuracy instead, with
almost perfect speciﬁcity again.
ARID1A/BAF250 is a nuclear protein that par-
ticipates in forming the SWI/SNF chromatin
remodeling complex. The protein is involved in
important cellular functions including transcription
modulation, DNA damage repair, DNA synthesis,
and DNA methylation. ARID1A acts as a tumor
suppressor. Inactivating mutations of ARID1A
result in loss of ARID1A protein expression, a
common condition in EC (23).
Fig. 2. (A) Assessment of risk of bias. Summary of risk of
bias for each study; Plus sign: low risk of bias; minus sign:
high risk of bias; question mark: unclear risk of bias. (B)
Risk of bias graph about each risk of bias item presented
as percentages across all included studies.
600 © 2019 APMIS. Published by John Wiley & Sons Ltd
RAFFONE et al.
ARID1A is one of the immunohistochemical
marker proposed by the 2017 ESGO guidelines to
diﬀerentiate premalignant EH from benign mimics
(24). However, the diagnostic accuracy of immuno-
histochemistry for ARID1A is anything but
deﬁned. We found that ARID1A loss was very little
sensitive (0.12) for premalignant EH. This ﬁnding
resulted in a suboptimal diagnostic accuracy
(LR+ = 4.34, LR = 0.85, DOR = 5.12), making
ARID1A inadequate as a diagnostic marker. On
Fig. 3. Forest plots reporting sensitivity, speciﬁcity, positive and negative likelihood ratios, and diagnostic odds ratio of
ARID1A as a diagnostic marker in the diﬀerential diagnosis between benign and premalignant endometrial hyperplasia.
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the other hand, the speciﬁcity of ARID1A as a
marker of premalignancy was almost perfect (0.99).
For this reason, ARID1A does not appear ade-
quate as a stand-alone diagnostic marker of prema-
lignant EH, but it may be useful as a ‘rule-in’ test
for diagnosis of precancer, due to its excellent
speciﬁcity. In our previous studies, we found that
Bcl-2 and PAX2 were speciﬁc marker of premalig-
nant EH (25), (26). On the other hand, PTEN,
which is considered the key molecule in endometrial
carcinogenesis, was too little speciﬁc to be clinically
useful (27–29). The combination of several speciﬁc
markers might constitute a highly accurate test for
EH diagnosis. An immunohistochemical panel of
diagnostic markers might be a little expensive solu-
tion to improve the histologic diagnosis of EH,
especially in diﬃcult cases. Our results suggest not
to use ARID1A as a stand-alone diagnostic mar-
ker. We think that information about the diagnos-
tic accuracy of ARID1A should be provided in the
next guidelines.
ARID1A has also been studied as a prognostic
marker in EH. Some studies showed that the rates
of ARID1A loss were higher in EC than in EH,
indirectly supporting a prognostic relevance of
ARID1A. Recently, the prognostic value of
ARID1A has been assessed more speciﬁcally, by
correlating its expression on preoperative EH
Fig. 4. Forest plots reporting sensitivity, speciﬁcity, positive and negative likelihood ratios, and diagnostic odds ratio of
ARID1A as a prognostic marker for occult cancer coexisting with endometrial hyperplasia.
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biopsies with the presence of occult cancer revealed
on a subsequent hysterectomy. Our study focused
on these novel data. We found that ARID1A loss
in premalignant EH was highly speciﬁc (0.99) for
coexistent cancer. Even in this case, sensitivity was
found low (0.33), but the prognostic accuracy was
good (DOR = 49.95). Furthermore, an excellent
LR + was observed (20.70).
These results support the usefulness of ARID1A
as a prognostic marker in EH. The excellent speci-
ﬁcity and LR+ may make immunohistochemistry
for ARID1A a valuable test to predict the presence
of EC coexisting with premalignant EH. Based on
the Fagan’s nomogram, ARID1A loss in atypical
EH/EIN may indicate a likelihood around 95% of
occult cancer (Fig. 5). Immunohistochemistry for
ARID1A may be crucial in the management of
patients diagnosed with EH, identifying cases at
very high risk of coexistent cancer. Firstly,
ARID1A loss may indicate the need for a more
careful diagnosis, in order not to miss an occult
cancer. Secondly, in patients eligible for
conservative treatment, ARID1A loss might lead to
perform a more careful evaluation of eligibility and
a closer follow-up, due to the high risk of cancer.
In fact, ARID1A loss was found to be associated
with myoinvasive EC (21). An intravenous con-
trast-enhanced abdomen and pelvis magnetic reso-
nance (recommended for conservative treatment of
EC, but not of EH) might be necessary in order to
conﬁrm the absence of myometrial or cervical inva-
sion, as well as extrauterine metastases (30).
Thirdly, ARID1A status may be crucial in the
assessment of eligibility for conservative treatment
in borderline cases, such as age around 40, pluri-
parity, wish to get pregnant not in the short term,
low couple fertility potential. Finally, in patient eli-
gible for hysterectomy, it might indicate a higher
surgical priority. Given all these observations,
ARID1A evaluation may add important diagnostic
and prognostic information in order to adopt a
more tailored approach to the patient. Such infor-
mation may be even more important if we consider
the wide range of available treatments for EH ad
EC (31–34) and the inaccuracy of the predictive
markers studied (35–39). To date, ARID1A appears
as the most promising prognostic marker in EH.
Indeed, although other immunohistochemical mark-
ers have been studied in this regard, including
PTEN, Bcl2, PAX2, b-catenin, and COX2, none of
them has shown a speciﬁcity comparable to
ARID1A (40), (41); similarly, clinical markers asso-
ciated with occult cancer in EH, such as diabetes
mellitus, appear unsuitable to be used as stand
alone for prognostic stratiﬁcation (42). The loss of
mismatch repair proteins expression might be
another promising prognostic marker in EH, but its
prevalence appears too low (43).Given its prognos-
tic accuracy, ARID1A might be assessed indepen-
dently from other markers and in all patents with
premalignant EH.
Further studies are necessary to conﬁrm the diag-
nostic and prognostic signiﬁcance and the clinical
applicability of immunohistochemistry for ARID1A
in EH.
Strengths and limitations
This is the ﬁrst meta-analysis assessing the signiﬁ-
cance of ARID1A in EH. We assessed a large sam-
ple and highlighted the novel and promising
ﬁndings regarding the prognostic value of
ARID1A.
A limitation of our study may lie in the lack of a
standardized method to interpret ARID1A
immunohistochemistry. This may be the cause of
the signiﬁcant heterogeneity in the sensitivity analy-
sis. We tried to reduce the heterogeneity by using
Fig. 5. Fagan’s nomogram reporting pre-test and post-test
probability of cancer coexisting with endometrial hyper-
plasia, in case of ARID1A loss (red line) and ARID1A
retained (blue line) at immunohistochemistry.
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only data regarding a complete loss of ARID1A
expression.
Another limitation is the presence of only two
studies in analysis of the prognostic value of
ARID1A; this aﬀected the assessment of hetero-
geneity, leading to an inconsistence of >50% in the
pooled speciﬁcity, despite the closeness of the val-
ues.
However, in both diagnostic and prognostic anal-
ysis, the results regarding speciﬁcity appeared to be
robust, ranging from 0.97 to 1.00 in all studies.
CONCLUSION
As a diagnostic marker of premalignant EH,
ARID1A loss has high speciﬁcity but low overall
accuracy, with a possible usefulness as a support
marker, particularly if integrated in an immunohis-
tochemical diagnostic panel.
On the other hand, ARID1A loss in premalig-
nant EH appears as an accurate and almost per-
fectly speciﬁc prognostic marker for coexistent
cancer. Immunohistochemistry for ARID1A might
be introduced in the clinical practice as a prognos-
tic test in premalignant EH. ARID1A immunohis-
tochemical status might be a crucial information
for a more tailored management of patients, aﬀect-
ing conservative treatment, surgical priority of hys-
terectomy, and evaluation of eligibility for
conservative approach in borderline cases.
Further studies are necessary to conﬁrm the clini-
cal applicability of ARID1A as a diagnostic and
prognostic test in EH.
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